Revenio Group Oyj
0KFH.L
London Stock Exchange20.82
EUR
-1.88
- -
Revenio Group Oyj
0KFH.L
(London Stock Exchange)
Recent
price
20.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Revenio Group Oyj is a Finland-based health technology company specializing in ophthalmic diagnostic devices and software solutions. Founded in 2001 and headquartered in Vantaa, Finland, the company develops, manufactures, and markets advanced medical diagnostic equipment focused on the early detection and monitoring of eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Revenio's core products include intraocular pressure (IOP) measurement devices (tonometers); fundus imaging devices; perimeters; and clinical software systems under the iCare brand, which offer efficient, fast, and reliable diagnostic tools for eye care professionals. The company’s software platform, Oculo, integrates clinical communication, telehealth, remote patient monitoring, and data analytics capabilities to streamline eye care services. Revenio operates internationally, with significant market presence in Finland, the United States, Europe, Asia-Pacific, and other regions. The company serves ophthalmologists, clinics, and health care providers by delivering a comprehensive portfolio of ophthalmic diagnostic products and digital solutions aimed at improving clinical diagnostics and care pathways. Revenio focuses on innovation through continuous product development, including AI-enhanced screening software like iCare ILLUME for early detection of eye diseases using artificial intelligence. Its strategic vision emphasizes transforming from a device manufacturer to a provider of holistic eye care solutions encompassing both hardware and software. In the last 1-2 years, Revenio Group has embarked on organizational development to become more customer-centric while advancing its growth strategy for 2024–2026. Key recent developments include product innovations such as the launch of upgraded versions of its tonometers including the HOME2 family and expansion of its software offerings incorporating AI diagnostics and telehealth functionalities. The company also secured approvals and certifications for new devices like micro perimeters to enhance its product range. Revenio continues to expand its global reach, notably growing its presence in markets like China and India. Additionally, management has undertaken operational changes to optimize clinical care pathways and improve sales and customer engagement, underpinning sustainable and profitable growth. Revenio Group Oyj maintains a focus on strengthening its competitive positioning with product quality and innovation while exploring potential operational adjustments such as supply chain and assembly optimizations in response to global market dynamics. The company’s leadership team includes CEO Jouni Erik Toijala and CTO Marco Rizzardo, and it operates as a publicly listed entity traded under the ticker 0KFH.L. Revenio leverages technology to address mounting eye care demands driven by aging populations and lifestyle-related diseases across diverse geographic markets. Overall, Revenio Group Oyj is a prominent global player in ophthalmological diagnostics, delivering integrated product and software solutions designed to enhance clinical efficiency and quality in eye care worldwide. Its continued innovation and strategic expansion have positioned it well for long-term growth in the evolving healthcare landscape.